The Hematology Society of Taiwan yesterday said acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow, can progress quickly and aggressively and urged the government to ...
Last month, the company said that SLS009 blocks key survival pathways that normally shield acute myeloid leukemia cells from natural programmed cell death, making them more vulnerable.
Precision Biologics, Inc. announces a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing truncated core 1 O-glycans will be presented ...
Delta-Fly Pharma Inc. is pressing ahead with discussions with the FDA for its lead acute myeloid leukemia (AML) candidate, radgocitabine (DFP-10917), despite a phase III miss on its primary endpoint, ...
Yale University student athletes from across campus volunteered at the eighteenth annual Mandi Schwartz Marrow Donor ...
Remedy Plan Therapeutics, a clinical-stage biotechnology company developing novel therapies that target fundamental metabolic vulnerabilities in disease, today announced that multiple abstracts will ...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the National Medical Products Administration (NMPA) has accepted the Investig ...
Bioscience Co. Ltd.’s has announced IND acceptance by China’s National Medical Products Administration (NMPA) for the company’s LILRB4/CD3 T-cell engager bispecific antibody 6MW5311. The drug ...
A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age ...
Researchers believe the therapy, which targets CD83, can selectively target leukemia cells and treat side effects of stem cell transplants.
Complete Information About Anchors, Anthems, and Ales at Bayboro Brewing in Tampa at Bayboro Brewing Co. A rock and roll ...
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF)SOUTH SAN FRANCISCO, Calif., April ...